Table 2.
Parameter Estimates of Longitudinal Modeling of Outcome Variables
| Parameter | Estimate | S.E.* | p-value |
|---|---|---|---|
| Model-I: CD4 T-Cell Counts | |||
| Time | -0.003 | 0.003 | 0.195 |
| Gender | -0.088 | 0.101 | 0.383 |
| Race | -0.238 | 0.101 | 0.018 |
| Treatment | |||
| Mono Therapy | 0.279 | 0.055 | <0.001 |
| Dual Therapy | 0.105 | 0.029 | <0.001 |
| HAART | 0.246 | 0.026 | <0.001 |
| Triple Nucleoside | 0.137 | 0.031 | <0.001 |
| Other Infections | -0.253 | 0.099 | 0.011 |
| Mode of Transmission | -0.165 | 0.146 | 0.257 |
| Model-II: CD4-Percent | |||
| Time | -0.019 | 0.049 | 0.698 |
| Gender | -2.513 | 2.402 | 0.296 |
| Race | -5.560 | 2.399 | 0.021 |
| Treatment | |||
| Mono Therapy | 5.871 | 1.282 | <0.001 |
| Dual Therapy | 2.889 | 0.677 | <0.001 |
| HAART | 5.174 | 0.609 | <0.001 |
| Triple Nucleoside | 3.142 | 0.728 | <0.001 |
| Other Infections | -6.975 | 2.365 | 0.003 |
| Mode of Transmission | -3.358 | 3.471 | 0.333 |
| Model-III: Viral Load | |||
| Time | -0.539 | 0.349 | 0.129 |
| Gender | -8.874 | 18.052 | 0.623 |
| Race | 4.825 | 18.013 | 0.789 |
| Treatment | |||
| Mono Therapy | -16.692 | 21.599 | 0.439 |
| Dual Therapy | -57.206 | 11.192 | <0.001 |
| HAART | -86.023 | 10.150 | <0.001 |
| Triple Nucleoside | -22.382 | 12.172 | 0.066 |
| Other Infections | 52.850 | 17.878 | 0.003 |
| Mode of Transmission | 18.669 | 26.681 | 0.484 |
*
Standard error